Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 16 Colorectal Neoplasms 7 Small Cell Lung Carcinoma 4 Neoplasm Metastasis 4 Stomach Neoplasms 3 Recurrence 3 Biliary Tract Neoplasms 3 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Ovarian Neoplasms 2 Nasopharyngeal Carcinoma 2 Fallopian Tube Neoplasms 2 Cholangiocarcinoma 2 Triple Negative Breast Neoplasms 1 Somatostatinoma 1 Solid Tumor 1 Small Cell Lung Cancer Extensive Stage 1 Small Bowel Adenocarcinoma 1 Rectal Neoplasms 1 Rectal Cancer Patients 1 Pancreatic Ductal Adenocarcinoma 1 Pancreatic Cancer Non-resectable 1 Pancreatic Cancer Metastatic to Liver 1 Pancreatic Adenocarcinoma 1 PDAC - Pancreatic Ductal Adenocarcinoma 1 Osteosarcoma 1 Neoplasms 1 Neoadjuvant Chemotherapy 1 Metastatic Pancreatic Adenocarcinoma 1 Locally Advanced Rectal Cancer (LARC) 1

Interventions

Fulvestrant 5 Letrozole 3 Capecitabine 3 ribociclib 2 exemestane 2 dalpiciclib 2 apatinib 2 Irinotecan 2 Gemcitabine 2 Anastrozole 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pegfilgrastim 1 palbociclib 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Vinorelbine 1 Trastuzumab 1 Tamoxifen 1 Paclitaxel 1 Liposomes 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Cancer Metastatic × irinotecan sucrosofate × Clear all

NCT03328884 2025-04-23

Phenomenal

MedSIR

Phase 2 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡